Cointime

Inhibrx

company

About

Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates.

  • 51 - 100

Highlights

Total Funding Amount
$40M
Funding Rounds
1
Investors
1

Details

Last Funding Type
Convertable Note
Last Funding Money Raised
$40M
Industries
Biotechnology,Therapeutics
Founded date
Jan 1, 2010
Number Of Employee
51 - 100
Operating Status
Active

Inhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The Inhibrx pipeline is focused on oncology, orphan diseases and infectious diseases. Inhibrx has collaborations with Celgene and bluebird bio and has received awards from several granting agencies, including NIH, NIAID and CARB-X.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$40M
Inhibrx has raised a total of $40M in funding over 2 rounds. Their latest funding was raised on May 21, 2019 from a Convertable Note round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 21, 2019 Convertable Note $40M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
1
Inhibrx is funded by 1 investors. Lilly Asia Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Lilly Asia Ventures — Convertable Note
Cointime
เนื้อหา
บริษัท